Literature DB >> 3027267

A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer.

W K Evans, D W Nixon, J M Daly, S S Ellenberg, L Gardner, E Wolfe, F A Shepherd, R Feld, R Gralla, S Fine.   

Abstract

One hundred ninety-two patients with previously untreated metastatic cancer (102 non-small-cell lung cancer [NSCLC]; 90 colorectal cancer) were randomized to receive either ad lib nutritional intake (control group) or specific nutritional intervention during a 12-week study period when chemotherapy was administered. Those patients randomized to nutritional interventions were counselled to take oral nutrients with caloric intake equal to 1.7 to 1.95 times their basal energy expenditure, depending on their pretreatment nutritional status ("standard" group). An augmented group was counselled to have a caloric intake equivalent to that of the standard group but with 25% of calories provided as protein and additional supplements of zinc and magnesium. Counselling increased caloric intake in both tumor types but reduced weight loss in the short term only for lung cancer patients. Ninety-three NSCLC patients were evaluable for tumor response to vindesine and cisplatin. Overall, only 20.4% of the patients responded, and there were no significant differences in response rates, median time to progression, or overall duration of survival between the nutrition intervention groups and the control group. The tumor response rate to time-sequenced 5-fluorouracil (5-FU) and methotrexate in the 81 evaluable patients with colorectal cancer was only 14.8%, and no significant differences in tumor response rates were noted between the three groups. Furthermore, the median time to progression and overall duration of survival were not different for the control, standard, and augmented groups. Nutritional interventions using dietary counselling had no impact on the percent of planned chemotherapy dose administered, the degree of toxicity experienced by patients, or the frequency of treatment delays. A multivariate prognostic factor analysis demonstrated that for lung cancer, the percent of weight loss, serum albumin concentration, and presence of liver metastases were significant (P less than .05) and independent prognostic variables for survival duration. For colorectal cancer, serum albumin, alkaline phosphatase, lactic dehydrogenase (LDH) levels, and percent targeted caloric intake (TCI) were significant independent predictors of survival duration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3027267     DOI: 10.1200/JCO.1987.5.1.113

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

1.  [Indication for artificial nutrition: enteral and parenteral nutrition].

Authors:  A Schneider; M Momma; M P Manns
Journal:  Internist (Berl)       Date:  2007-10       Impact factor: 0.743

2.  Nutritional therapy for cancer cachexia.

Authors:  R F Grimble
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

3.  Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.

Authors:  Jane A Read; Philip J Beale; Dianne H Volker; Narelle Smith; Annabel Childs; Stephen J Clarke
Journal:  Support Care Cancer       Date:  2006-10-05       Impact factor: 3.603

Review 4.  Nutrient restriction and radiation therapy for cancer treatment: when less is more.

Authors:  Colin E Champ; Renato Baserga; Mark V Mishra; Lianjin Jin; Federica Sotgia; Michael P Lisanti; Richard G Pestell; Adam P Dicker; Nicole L Simone
Journal:  Oncologist       Date:  2013-01-08

5.  Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial.

Authors:  K C H Fearon; M F Von Meyenfeldt; A G W Moses; R Van Geenen; A Roy; D J Gouma; A Giacosa; A Van Gossum; J Bauer; M D Barber; N K Aaronson; A C Voss; M J Tisdale
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

6.  Routine protein energy supplementation in adults: systematic review.

Authors:  J Potter; P Langhorne; M Roberts
Journal:  BMJ       Date:  1998-08-22

7.  Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle.

Authors:  Laura A A Gilliam; Leonardo F Ferreira; Joseph D Bruton; Jennifer S Moylan; Håkan Westerblad; Daret K St Clair; Michael B Reid
Journal:  J Appl Physiol (1985)       Date:  2009-09-24

Review 8.  Does nutrition support during chemotherapy increase long-term survival of cancer patients? Lessons from the past and future perspectives.

Authors:  Federico Bozzetti
Journal:  Support Care Cancer       Date:  2021-07-26       Impact factor: 3.603

9.  Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.

Authors:  Oscar Arrieta; Rosa M Michel Ortega; Geraldine Villanueva-Rodríguez; Maria G Serna-Thomé; Diana Flores-Estrada; Consuelo Diaz-Romero; Cindy M Rodríguez; Luis Martínez; Karla Sánchez-Lara
Journal:  BMC Cancer       Date:  2010-02-21       Impact factor: 4.430

Review 10.  A descriptive review of the factors contributing to nutritional compromise in patients with head and neck cancer.

Authors:  Martin R Chasen; Ravi Bhargava
Journal:  Support Care Cancer       Date:  2009-07-18       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.